Home-Based tDCS for Depression in BPD
Key facts
- Where
- Montreal, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06972368, who can take part
Where in Canada
- IUSMMMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ciusss de L'Est de l'Île de Montréal
- Trial code
- NCT06972368
- Record updated
- 6 May 2026
- Original description
The present study aims to assess the feasibility of home-based tDCS in remote and urban areas (primary objective).Read full original descriptionShow less
Efficacy Study of Enhanced Home-Based Transcranial Direct Current Stimulation (tDCS) on Depressive Symptoms in Borderline Personality Disorder (BPD): A Pilot Randomized Controlled Trial
The present study aims to assess the feasibility of home-based tDCS in remote and urban areas (primary objective).
The secondary aim is to obtain a preliminary assessment of the efficacy of 14 home-based tDCS sessions in reducing depressive symptoms in BPD patients with moderate to severe depressive episodes and BPD symptoms.
Exploratory objectives include assessing the impact on neuropsychological and psychosocial functioning, anxiety, physical activity, sleep disorders, and addiction.
Additionally, we aim to investigate the sociodemographic and clinical factors that are linked to the most favorable response to tDCS in addressing both depressive and BPD symptoms.
We also aim to assess the feasibility of using a smartwatch as an outcome measure in this population.
Finally, we intend to gather preliminary data on the effectiveness of an online psychoeducational program specifically designed for patients with BPD.
Researchers will compare active tDCS to sham tDCS to see if active treatment is more effective in treating depression in this population.
Participants will:
* Receive 14 sessions of either active or sham tDCS over one week, delivered at home * Complete psychological and neurocognitive assessments at baseline, post-treatment, and at 6 weeks * Wear actigraphy monitors and complete questionnaires to assess sleep, physical activity, and other mental health outcomes
This trial will also explore the feasibility of delivering tDCS in both urban and rural settings.
Inclusion: To be aged between 18 and 65; To meet the DSM-IV criteria for BPD; To present a moderate depressive episode, defined as a MADRS score ≥ 20 (V1 and V3); To be capable to consent to participate in the study; To speak either French or English; Participants must have a prescribing doctor or mental health professional responsible; To maintain a stable psychopharmacological and psychotherapeutic intervention; To have access to internet an a smartphone; To demonstrate proficiency in independently using a tDCS device; To be able to pick up and return the remote tDCS device.
Exclusion: To be pregnant. 8. To be currently undergoing neuromodulation treatment. 9. To be currently using benzodiazepines; 1. To have a history of Epilepsy. 2. To have a contraindication for tDCS Medical Devices. 3. To have a history of Cerebrovascular Surgery. 4. To present scalp Conditions Affecting tDCS Electrode Placement. 5. To have a history of bipolar disorder. 6. To present social or medical conditions limiting the autonomous use of remote tDCS.